Wegovy vs Mounjaro: Semaglutide and Tirzepatide Compared

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

A PlexusDx Education Hub breakdown focused on the two molecules at the center of the GLP-1 conversation. Browse the Peptides & GLP-1 Education Hub

This is an independent editorial comparison; PlexusDx has no commercial relationship with the manufacturers of the products discussed.

Wegovy and Mounjaro headline the weight-management discussion, but the more useful contrast is between the molecules inside them — semaglutide and tirzepatide. As of April 2026, this breakdown puts the two compounds side by side, traces the class approval timeline, and lands on the genetics that sit upstream of any incretin decision.

Semaglutide and tirzepatide, side by side

Wegovy (semaglutide, Novo Nordisk) is a GLP-1 pathway compound, while Mounjaro (tirzepatide, Eli Lilly) is a GIP/GLP-1 dual agonist. Tirzepatide engages both incretin receptors; semaglutide, liraglutide, and dulaglutide are GLP-1-selective; retatrutide is an investigational GLP-1/GIP/glucagon triple agonist not FDA-approved as of April 2026. All act on the GLP-1 receptor to influence gastric emptying, glucose excursions, and satiety.

The approval timeline for the incretin class

Approvals are indication-specific and span more than a decade. Ozempic (semaglutide) reached type 2 diabetes in 2017; Wegovy (semaglutide 2.4 mg) reached chronic weight management in 2021; Rybelsus (oral semaglutide) diabetes in 2019; Mounjaro (tirzepatide) diabetes in 2022; Zepbound (tirzepatide) weight management in 2023 and obstructive sleep apnea in 2024 (SURMOUNT-OSA); Trulicity (dulaglutide) diabetes in 2014; Victoza (liraglutide) diabetes in 2010. Retatrutide is investigational.

What the trial programs actually measured

The evidence base is a set of distinct programs. STEP measured semaglutide for weight management; SUSTAIN and SELECT covered semaglutide for diabetes and cardiovascular outcomes; SURMOUNT and SURPASS covered tirzepatide; SURMOUNT-OSA addressed sleep apnea; LEAD and LEADER covered liraglutide; AWARD covered dulaglutide. Direct comparisons are scarce — SUSTAIN 7 and SURPASS-2 stand out — so the cleanest interpretation stays per-trial rather than sweeping.

A single safety framework for the category

Every FDA-approved GLP-1 receptor agonist and GIP/GLP-1 dual agonist carries the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and all are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal symptoms are the most common effects; rare serious events include pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

What the branded field costs at list

As of April 2026, list prices for the FDA-approved brands range roughly $815 to $1,620 per month at U.S. list (manufacturer published pricing). Semaglutide and tirzepatide products fall within that band at different points, and the figure a person ultimately pays depends on insurance coverage, the indication on the prescription, savings card eligibility, and whether a compounded alternative is available through a licensed compounding pathway.

Genes upstream of every incretin decision

Whichever molecule a clinician selects, the genetic architecture is shared. Variants in FTO (appetite and adiposity set-point), GLP1R (the receptor every GLP-1 compound engages), MC4R (energy balance), and TCF7L2 (glucose homeostasis and GLP-1 secretion) shape the terrain semaglutide or tirzepatide has to work on. They are pathway-level and do not predict response. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — and the Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including FTO, GLP1R, MC4R, and TCF7L2.

More from the Hub: getting Wegovy online, Wegovy availability near you, the Wegovy injection, and coupons without insurance.

A note on scope: everything here is educational. Within the GLP-1 category PlexusDx supplies only semaglutide and tirzepatide through its Weight Management Protocols and neither sells, prescribes, nor recommends any other therapeutic peptide, dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds included. The Precision Peptide Genetic Test reflects how genes shape peptide-related pathways and cannot predict how you will respond to a given medication. Talk with a qualified healthcare provider before starting any peptide protocol.

Ground the decision in your own data: take the Precision Peptide Genetic Test, then review the Weight Management Protocols. Browse the Peptides & GLP-1 Education Hub

Frequently Asked Questions

What's the practical difference between semaglutide and tirzepatide?

Semaglutide is a GLP-1-selective agonist, while tirzepatide engages both the GIP and GLP-1 receptors. That extra incretin arm is the core molecular distinction between Wegovy and Mounjaro. Dosing schedules and half-lives also differ, which shapes how each is administered and titrated under clinical supervision.

Are oral and injectable versions interchangeable?

Not automatically. Oral and injectable formulations differ in absorption, dosing, and approved indications, so they are not swapped one-for-one. Rybelsus is oral semaglutide approved for type 2 diabetes, for example, while Wegovy is injectable. Any change of format is a clinical decision made with your prescriber.

Can the Precision Peptide Genetic Test recommend a compound?

No. It does not predict response to Wegovy, Mounjaro, or any medication and makes no treatment recommendation. It reads pathway-level variants — FTO, GLP1R, MC4R, and TCF7L2 — that describe your baseline GLP-1 and energy-balance biology, the upstream context that applies to both semaglutide and tirzepatide.

What drives the $800-plus price spread?

That $815-to-$1,620 April 2026 band exists because separate manufacturers, molecules, and indications populate the branded field. Any one product occupies a single point in the range, and what you actually pay hinges on coverage, savings cards, the prescribed indication, and whether a compounded alternative is accessible.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.